statements

The stock has been placed in Additional Surveillance Measure (ASM) list LTASM - I.

The stock has been placed in Graded Surveillance Measure (GSM) list GSM - 0.

Genomic Valley Biotech Ltd.

BSE: 539206

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Biotechnology

30.50+0.1 (+0.36%)

9 Jul, 12:30 PM

Overview Analysis Statements

Technicals Forecast Peers Resources News

Income Statement

Abridged

Understanding Income Statement

Genomic Valley Biotech Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	0.99	0.85	0.21	0.07	2.72	0.17	0.84	0.27
Cost of Operating Revenue	0.24	0.11	0.27	0.09	1.59	-	0.20	0.00
Gross Profit	0.74	0.74	-0.06	-0.02	1.13	0.17	0.64	0.26
Gross Margin	75.5	86.9	-30.1	-22.3	41.5	100.0	75.8	98.6
Total Operating Expenses	0.75	0.46	0.53	0.53	1.85	0.15	0.41	0.23
Operating Profit	0.23	0.38	-0.32	-0.46	0.87	0.01	0.44	0.04
Operating Margin	23.7	45.1	-155.9	-647.2	32.0	8.3	51.8	15.0
Financing Income/(Expense) - Net	0.00	-0.18	-0.18	0.04	0.04	-	-	-
Profit before Taxes	0.23	0.21	-0.50	0.00	0.65	0.02	0.44	0.04
Income Taxes	0.00	-0.08	0.06	0.01	0.00	0.00	0.09	0.01
Profit after Tax	0.23	0.29	-0.56	-0.01	0.65	0.02	0.36	0.03
PAT Margin	23.6	33.8	-268.7	-13.2	23.8	9.2	42.2	11.3
EPS - Basic - ex Extraordinary Items	0.76	0.94	-1.83	-0.03	2.12	0.05	1.17	0.10
EPS - Diluted - ex Extraordinary Items	0.76	0.94	-1.83	-0.03	2.12	0.05	1.17	0.10
EBIT	0.23	0.38	-0.32	-0.46	0.87	0.01	0.44	0.04
EBITDA	0.43	0.56	-0.14	-0.37	0.88	0.01	0.44	0.04
EBITDA Margin	43.4	66.2	-65.0	-527.7	32.3	8.9	52.1	16.4

Balance Sheet

Abridged

Understanding Balance Sheet

Genomic Valley Biotech Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	0.30	0.40	0.16	1.14	2.58	2.91	2.62	2.70
Long-Term Investments	-	-	-	-	-	0.02	-	-
Property Plant & Equipment - Net	4.80	4.94	6.33	1.75	0.00	0.00	0.01	0.00
Total Non-Current Assets	6.88	7.60	7.45	2.66	1.84	1.42	1.73	1.55
Total Assets	7.18	8.01	7.62	3.80	4.42	4.33	4.36	4.25
Total Current Liabilities	0.07	0.77	0.87	0.21	0.89	0.79	0.46	0.32
Long Term Debt	1.48	1.48	1.55	-	-	-	-	-
Total Non-Current Liabilities	2.34	2.19	2.26	0.70	0.00	0.00	0.00	0.00
Total Liabilities	2.42	2.96	3.13	0.92	0.89	0.79	0.46	0.32
Total Shareholders' Equity	4.76	5.05	4.49	2.88	3.53	3.54	3.90	3.93
Total Equity	4.76	5.05	4.49	2.88	3.53	3.54	3.90	3.93
Total Liabilities & Equity	7.18	8.01	7.62	3.80	4.42	4.33	4.36	4.25

Cash Flow

Abridged

Understanding Cash Flow Statement

Genomic Valley Biotech Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	0.41	0.38	-0.31	-0.76	0.92	0.01	0.35	0.03
Working Capital - Increase/(Decrease)	-1.45	0.06	1.80	-1.45	-1.66	-0.03	-0.33	-0.05
Net CF from Operating Activities	-1.04	0.44	1.48	-2.21	-0.74	-0.02	0.03	-0.02
Capital Expenditures - Net	-0.36	0.48	1.58	-5.35	-1.48	-	0.01	-
Net CF from Investing Activities	0.37	-0.48	-1.58	3.75	1.48	-0.02	0.01	-
Debt - LT & ST - Issuance/(Retirement) - Total	0.73	-	0.07	-1.55	-0.70	-	-	-
Net Cash Flow from Financing Activities	0.73	-	0.07	-1.55	-0.70	-	-	-
Free Cash Flow to Equity	0.05	-0.04	-0.03	1.59	0.04	-0.02	0.02	-0.02
Free Operating CF net dividend	-	-0.04	-0.09	-	-	-0.02	0.02	-0.02
Free Operating CF	-	-0.04	-0.09	-	-	-0.02	0.02	-0.02

Business Segment Analysis

Genomic Valley Biotech Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

We don't have enough data to show business segment analysis for Genomic Valley Biotech Ltd.

Regional Segment Analysis

Genomic Valley Biotech Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Genomic Valley Biotech Ltd.

Historical Segment Analysis

Track how Genomic Valley Biotech Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

We don't have enough data to show segments for Genomic Valley Biotech Ltd.

Frequently Asked Questions

What is the revenue of Genomic Valley Biotech Ltd.?

The latest trailing twelve month revenue of Genomic Valley Biotech Ltd. is ₹ 0.27 Cr, reflecting a 1-year growth of -68.30% and a 3-year CAGR of -53.86%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Genomic Valley Biotech Ltd.?

The latest trailing twelve month net profit (PAT) of Genomic Valley Biotech Ltd. is ₹ 0.03 Cr, with a 3-year earnings CAGR of -63.88%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Genomic Valley Biotech Ltd.?

The trailing twelve month EBITDA of Genomic Valley Biotech Ltd. is approximately ₹ 0.04 Cr (based on an operating margin of 14.97%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Genomic Valley Biotech Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Genomic Valley Biotech Ltd. is 0.10. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Genomic Valley Biotech Ltd.?

The debt-to-equity ratio of Genomic Valley Biotech Ltd. stands at 0.00. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Genomic Valley Biotech Ltd.?

The estimated book value per share of Genomic Valley Biotech Ltd. is 12.91 (derived from a P/B ratio of 2.36 and market price of ₹ 30.50), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Genomic Valley Biotech Ltd.?

The trailing twelve month operating cash flow of Genomic Valley Biotech Ltd. is ₹ -0.02 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Genomic Valley Biotech Ltd. report consolidated or standalone financials?

Genomic Valley Biotech Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.